Development of co-solvent freeze-drying method for the encapsulation of water-insoluble THIOSTREPTON (cas 1393-48-2) in sterically stabilized micelles

Add time:09/02/2019    Source:sciencedirect.com

The purpose of this work was to develop a practical and scalable method to encapsulate the hydrophobic antibiotic THIOSTREPTON (cas 1393-48-2) (TST) in sterically stabilized micelles (SSM). Using the conventional method of thin-film hydration, we encapsulated up to 5 drug molecules per SSM (diameter ∼ 16 nm). However, since this method is not suitable for large-scale production – a limiting factor for clinical translation – we applied the co-solvent freeze-drying method using tert-butanol (TBA): water co-solvent system. We found that the presence of phosphate-buffered saline (PBS) salts in the lyophilized cake accelerated the reconstitution time and allowed efficient drug encapsulation without the formation of larger drug particles. In addition, TBA proportion of 50% (v/v) was sufficient to maintain both phospholipid and drug in solution prior to the freeze-drying. The increase of drug and phospholipid concentrations in the formulation extended the reconstitution time and led to drug precipitation. Therefore, to increase the strength of the formulation, we prepared lyophilized cakes with lower phospholipid content (5 mM) and reconstituted them in one-third of the fill volume. In conclusion, we found optimum conditions to prepare TST-SSM using the co-solvent freeze-drying method. This scalable production method can facilitate the further clinical development and industrial production of TST-SSM nanomedicine.

We also recommend Trading Suppliers and Manufacturers of THIOSTREPTON (cas 1393-48-2). Pls Click Website Link as below: cas 1393-48-2 suppliers

Prev:Short communicationTranscript-level responses of Plasmodium falciparum to THIOSTREPTON (cas 1393-48-2)
Next:Discovery and efficient synthesis of a biologically active alkaloid inspired by THIOSTREPTON (cas 1393-48-2) biosynthesis)